Free Trial

NRx Pharmaceuticals (NRXP) Competitors

NRx Pharmaceuticals logo
$2.59 -0.10 (-3.72%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.01 (+0.42%)
As of 08/1/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRXP vs. CGC, FDMT, YMAB, OGI, ENGN, RAPT, CTMX, CYBN, SXTC, and CRBU

Should you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Canopy Growth (CGC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Organigram Global (OGI), enGene (ENGN), Rapt Therapeutics (RAPT), CytomX Therapeutics (CTMX), Cybin (CYBN), China SXT Pharmaceuticals (SXTC), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry.

NRx Pharmaceuticals vs. Its Competitors

Canopy Growth (NASDAQ:CGC) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Canopy Growth had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 3 mentions for Canopy Growth and 1 mentions for NRx Pharmaceuticals. Canopy Growth's average media sentiment score of 0.51 beat NRx Pharmaceuticals' score of 0.30 indicating that Canopy Growth is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Canopy Growth
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NRx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NRx Pharmaceuticals has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. NRx Pharmaceuticals' return on equity of 0.00% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Canopy Growth-195.76% -88.54% -40.78%
NRx Pharmaceuticals N/A N/A -355.00%

NRx Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 1,000.39%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NRx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

NRx Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$225.65M0.95-$429.86M-$4.04-0.26
NRx PharmaceuticalsN/AN/A-$25.13M-$2.01-1.29

Canopy Growth has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 1.3% of Canopy Growth shares are held by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NRx Pharmaceuticals beats Canopy Growth on 11 of the 16 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRXP vs. The Competition

MetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$46.51M$2.46B$5.48B$9.51B
Dividend YieldN/A1.81%4.73%4.09%
P/E Ratio-1.298.9728.6723.80
Price / SalesN/A437.63373.9066.58
Price / CashN/A157.7635.4557.96
Price / Book-1.754.838.275.55
Net Income-$25.13M$31.62M$3.24B$259.03M
7 Day Performance-13.67%-5.28%-3.69%-4.59%
1 Month Performance-21.99%4.38%4.33%4.46%
1 Year Performance22.17%-2.49%25.95%18.03%

NRx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRXP
NRx Pharmaceuticals
2.766 of 5 stars
$2.59
-3.7%
$28.50
+1,000.4%
+20.5%$46.51MN/A-1.292
CGC
Canopy Growth
0.6272 of 5 stars
$1.12
+2.8%
N/A-84.5%$200.41M$225.65M-0.283,150News Coverage
Upcoming Earnings
FDMT
4D Molecular Therapeutics
2.5461 of 5 stars
$4.24
+0.5%
$29.56
+597.1%
-62.7%$195.49M$40K-1.33120News Coverage
Upcoming Earnings
Analyst Forecast
Gap Up
YMAB
Y-mAbs Therapeutics
2.223 of 5 stars
$4.33
+0.5%
$15.60
+260.3%
-61.1%$195.17M$87.68M-6.77150News Coverage
Short Interest ↑
OGI
Organigram Global
1.1589 of 5 stars
$1.46
+0.7%
N/A-15.3%$194.21M$117.47M14.60860News Coverage
ENGN
enGene
3.4672 of 5 stars
$3.85
+1.6%
$23.29
+504.8%
-56.5%$193.69MN/A-2.3331
RAPT
Rapt Therapeutics
4.0217 of 5 stars
$11.70
+0.2%
$19.80
+69.2%
-58.0%$193.14M$1.53M-0.6180Upcoming Earnings
Analyst Upgrade
Gap Down
CTMX
CytomX Therapeutics
4.0091 of 5 stars
$2.38
-0.4%
$5.33
+124.1%
+75.4%$192.28M$138.10M4.96170News Coverage
Upcoming Earnings
Analyst Forecast
CYBN
Cybin
2.5864 of 5 stars
$8.03
-3.5%
$85.00
+958.5%
N/A$191.56MN/A-1.8350High Trading Volume
SXTC
China SXT Pharmaceuticals
0.911 of 5 stars
$1.62
-1.3%
N/A-80.3%$191.04M$1.93M0.0090News Coverage
Analyst Upgrade
CRBU
Caribou Biosciences
2.4417 of 5 stars
$2.07
+1.0%
$8.50
+310.6%
-12.9%$190.66M$9.99M-1.28100Upcoming Earnings
Gap Down

Related Companies and Tools


This page (NASDAQ:NRXP) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners